Rhabdomyolysis associated with concomitant use of colchicine and statins in the real world: identifying the likelihood of drug–drug interactions through the FDA adverse event reporting system DOI Creative Commons
Sha Zhang, Mingming Yan, Hui Zhao

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 16, 2024

Background Currently, there remains substantial controversy in research regarding whether the concomitant use of colchicine and statins increases occurrence rhabdomyolysis, warranting further substantiation. Objective This study aimed to identify likelihood drug-drug interactions (DDIs) for co-administration resulting rhabdomyolysis. Methods A disproportionality analysis was conducted by using data sourced from US Food Drug Administration Adverse Event Reporting System (FAERS) detect rhabdomyolysis signals associated with combined statins. The association between (colchicine/statins/colchicine statins) were evaluated information component (IC). DDI calculated based on Ω shrinkage measure Bayesian confidence propagation neural network (BCPNN) method. Furthermore, stratification performed individual agents. Results In total, 11,119 reports identified FAERS database, 255 (2.29%) involved both Our showed potential (Ω 025 = 1.17) among individuals concurrent Moreover, drug-specific suggests colchicine-atorvastatin pair 1.12), colchicine-rosuvastatin 1.05), along a higher proportion (IC 5.20) 4.26), respectively. Conclusion findings suggest that may increase risk particularly when atorvastatin or rosuvastatin. Therefore, healthcare professionals should pay special attention life-threatening AE such as co-prescribing

Language: Английский

Rhabdomyolysis associated with concomitant use of colchicine and statins in the real world: identifying the likelihood of drug–drug interactions through the FDA adverse event reporting system DOI Creative Commons
Sha Zhang, Mingming Yan, Hui Zhao

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 16, 2024

Background Currently, there remains substantial controversy in research regarding whether the concomitant use of colchicine and statins increases occurrence rhabdomyolysis, warranting further substantiation. Objective This study aimed to identify likelihood drug-drug interactions (DDIs) for co-administration resulting rhabdomyolysis. Methods A disproportionality analysis was conducted by using data sourced from US Food Drug Administration Adverse Event Reporting System (FAERS) detect rhabdomyolysis signals associated with combined statins. The association between (colchicine/statins/colchicine statins) were evaluated information component (IC). DDI calculated based on Ω shrinkage measure Bayesian confidence propagation neural network (BCPNN) method. Furthermore, stratification performed individual agents. Results In total, 11,119 reports identified FAERS database, 255 (2.29%) involved both Our showed potential (Ω 025 = 1.17) among individuals concurrent Moreover, drug-specific suggests colchicine-atorvastatin pair 1.12), colchicine-rosuvastatin 1.05), along a higher proportion (IC 5.20) 4.26), respectively. Conclusion findings suggest that may increase risk particularly when atorvastatin or rosuvastatin. Therefore, healthcare professionals should pay special attention life-threatening AE such as co-prescribing

Language: Английский

Citations

1